Seegene (KSDQ:096530) said today that it inked a collaboration deal with Hologic (NSDQ:HOLX) to develop high-multiplex, real-time PCR reagents for the developing Hologic Panther Fusion system.
According to the agreement, Seegene will develop and manufacture multiplex assays for Hologic’s next-gen molecular diagnostics platform; Hologic will receive worldwide commercialization rights to the assays. Financial terms of the deal were not disclosed.
Get the full story at our sister site, Drug Delivery Business News.
The post Hologic inks collab deal with Seegene appeared first on MassDevice.
from MassDevice http://ift.tt/2ejmKuP
Cap comentari:
Publica un comentari a l'entrada